Lisa M. Neff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lisa M. Neff has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Jaime P. Almandoz
Department of Internal Medicine University of Texas Southwestern Medical Center Dallas Texas USA
5 shared publications - Kristina Secnik Boye
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, USA
5 shared publications Angela Fitch
Knownwell Boston Massachusetts USA
3 shared publications- Caroline M. Apovian
Division of Endocrinology, Diabetes, and Hypertension Brigham and Women's Hospital Boston Massachusetts USA
3 shared publications - Chisom Kanu
Eli Lilly and Company, Indianapolis, IN, USA
3 shared publications - Colleen Tewksbury
Department of Surgery University of Pennsylvania Philadelphia Pennsylvania USA
3 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
Screening for Nutritional Risk in Adults Receiving Obesity Treatment: A Systematic Literature Review of Available Tools and Identification of Conceptual Gaps
Aims: Identify nutrition screening tools used in obesity research and qualitatively assess their appropriateness for evaluating nutritional risk in adults receiving obesity treatment, including with obesity management medications (OMMs) in outpatient clinical settings. Materials and Methods: A systematic review of MEDLINE and Embase (29‐January‐2026) along with relevant conference websites (22‐March‐2026) targeted published studies in English of non‐hospitalized adults with obesity or overweight that used a screening tool for nutritional risk (inadequate dietary intake and/or undernutrition). Studies were manually reviewed and summarized to identify tools. Identified tools were obtained and considered for practical use in outpatient settings (e.g., length, complexity). Practical tools were qualitatively assessed for capture of clinically‐informed nutritional risk concepts in obesity treatment (e.g., weight loss, energy intake and gastrointestinal symptoms). Results: Sixteen studies met inclusion criteria and were summarized. Semi‐quantitative food frequency questionnaires ( n = 11) and an unavailable nutrition performance questionnaire ( n = 1) did not meet practical considerations. Three tools were qualitatively assessed: International Federation of Gynaecology and Obstetrics (FIGO) Nutrition Checklist, Simplified Nutritional Appetite Questionnaire (SNAQ) and Rapid Eating Assessment for Participants–Short Form (REAP‐S). Concepts relevant to nutritional risk with obesity treatment were not adequately captured by these identified tools. Notable missing concepts included weight loss, fluid intake, gastrointestinal symptoms, history of bariatric surgery and comorbid conditions. Conclusions: Identified tools did not capture key concepts for assessing nutritional risk in adults receiving obesity treatment. Thus, development of new nutrition screening tools is needed to capture these concepts in ways that are actionable for clinicians in general outpatient settings.
- 9 November 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
Open AccessScreening for Nutritional Risk in Adults Receiving Obesity Treatment: A Systematic Literature Review of Available Tools and Identification of Conceptual Gaps
Aims: Identify nutrition screening tools used in obesity research and qualitatively assess their appropriateness for evaluating nutritional risk in adults receiving obesity treatment, including with obesity management medications (OMMs) in outpatient clinical settings. Materials and Methods: A systematic review of MEDLINE and Embase (29‐January‐2026) along with relevant conference websites (22‐March‐2026) targeted published studies in English of non‐hospitalized adults with obesity or overweight that used a screening tool for nutritional risk (inadequate dietary intake and/or undernutrition). Studies were manually reviewed and summarized to identify tools. Identified tools were obtained and considered for practical use in outpatient settings (e.g., length, complexity). Practical tools were qualitatively assessed for capture of clinically‐informed nutritional risk concepts in obesity treatment (e.g., weight loss, energy intake and gastrointestinal symptoms). Results: Sixteen studies met inclusion criteria and were summarized. Semi‐quantitative food frequency questionnaires ( n = 11) and an unavailable nutrition performance questionnaire ( n = 1) did not meet practical considerations. Three tools were qualitatively assessed: International Federation of Gynaecology and Obstetrics (FIGO) Nutrition Checklist, Simplified Nutritional Appetite Questionnaire (SNAQ) and Rapid Eating Assessment for Participants–Short Form (REAP‐S). Concepts relevant to nutritional risk with obesity treatment were not adequately captured by these identified tools. Notable missing concepts included weight loss, fluid intake, gastrointestinal symptoms, history of bariatric surgery and comorbid conditions. Conclusions: Identified tools did not capture key concepts for assessing nutritional risk in adults receiving obesity treatment. Thus, development of new nutrition screening tools is needed to capture these concepts in ways that are actionable for clinicians in general outpatient settings.
- Open Access
- 23 May 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (8) , 3552-3567
Psychometric Validation of the Weight and Emotions Scale (WES) in Adults with Obesity or Overweight
Individuals with obesity or overweight experience a substantial socioemotional burden and lower quality of life. Existing patient-reported outcome (PRO) instruments do not adequately measure emotional functioning concepts important to individuals with obesity/overweight. This study describes the psychometric properties of the Weight and Emotions Scale (WES), a new PRO measure to evaluate emotional functioning in adults with obesity or overweight. 120 adults completed two web-based surveys (baseline, week 2). Survey 1 comprised the 16-item WES, Control of Eating Questionnaire, Impact of Weight on Quality of Life-Lite Clinical Trials Version, Impact of Weight on Self-Perceptions Questionnaire, and Patient Global Impression of Severity (PGIS) 'Overall Emotional Impact of Weight.' Survey 2 included the WES and PGIS 'Overall Emotional Impact of Weight.' Factor structure, reliability, and validity of the WES were assessed. Exploratory factor analysis of the WES supported a two-factor structure as items loaded strongly (≥ 0.59) on factors corresponding to positive and negative feelings. The unidimensional framework was revised to include two WES domains ('Positive Feelings' [8 items] and 'Negative Feelings' [8 items]). The WES domain and total scores demonstrated excellent internal consistency (Cronbach's alpha ≥ 0.90) and good test-retest reliability (intraclass correlation coefficient: 0.87-0.89). Convergent validity of the WES was demonstrated via large correlations with the Impact of Weight on Quality of Life-Lite Clinical Trials Version 'Psychosocial' score and items, Impact of Weight on Self-Perceptions Questionnaire total score, and PGIS 'Overall Emotional Impact of Weight.' Known-groups validity was demonstrated via higher WES domain and total scores in participants who reported feeling good about their weight (PGIS 'Overall Emotional Impact of Weight'). The final version of the WES with 16 items is a reliable and valid PRO measure for assessing emotional functioning in individuals with obesity or overweight, with potential utility in observational studies, clinical trials, and clinical practice.
- 23 May 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (8) , 3552-3567
Open AccessPsychometric Validation of the Weight and Emotions Scale (WES) in Adults with Obesity or Overweight
Individuals with obesity or overweight experience a substantial socioemotional burden and lower quality of life. Existing patient-reported outcome (PRO) instruments do not adequately measure emotional functioning concepts important to individuals with obesity/overweight. This study describes the psychometric properties of the Weight and Emotions Scale (WES), a new PRO measure to evaluate emotional functioning in adults with obesity or overweight. 120 adults completed two web-based surveys (baseline, week 2). Survey 1 comprised the 16-item WES, Control of Eating Questionnaire, Impact of Weight on Quality of Life-Lite Clinical Trials Version, Impact of Weight on Self-Perceptions Questionnaire, and Patient Global Impression of Severity (PGIS) 'Overall Emotional Impact of Weight.' Survey 2 included the WES and PGIS 'Overall Emotional Impact of Weight.' Factor structure, reliability, and validity of the WES were assessed. Exploratory factor analysis of the WES supported a two-factor structure as items loaded strongly (≥ 0.59) on factors corresponding to positive and negative feelings. The unidimensional framework was revised to include two WES domains ('Positive Feelings' [8 items] and 'Negative Feelings' [8 items]). The WES domain and total scores demonstrated excellent internal consistency (Cronbach's alpha ≥ 0.90) and good test-retest reliability (intraclass correlation coefficient: 0.87-0.89). Convergent validity of the WES was demonstrated via large correlations with the Impact of Weight on Quality of Life-Lite Clinical Trials Version 'Psychosocial' score and items, Impact of Weight on Self-Perceptions Questionnaire total score, and PGIS 'Overall Emotional Impact of Weight.' Known-groups validity was demonstrated via higher WES domain and total scores in participants who reported feeling good about their weight (PGIS 'Overall Emotional Impact of Weight'). The final version of the WES with 16 items is a reliable and valid PRO measure for assessing emotional functioning in individuals with obesity or overweight, with potential utility in observational studies, clinical trials, and clinical practice.
- 10 April 2026
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Association Between Body Composition Measures and Cardiometabolic Outcomes: A Systematic Review Protocol
INPLASY202640036 Association Between Body Composition Measures and Cardiometabolic Outcomes: A Systematic Review Protocol Keywords: Obesity; Overweight; Cardiometabolic outcomes; Systematic literat…
- 10 April 2026
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Association Between Body Composition Measures and Cardiometabolic Outcomes: A Systematic Review Protocol
INPLASY202640036 Association Between Body Composition Measures and Cardiometabolic Outcomes: A Systematic Review Protocol Keywords: Obesity; Overweight; Cardiometabolic outcomes; Systematic literat…
- Top Cited PapersOpen Access
- 23 January 2026
- Published by Elsevier in Obesity Pillars
- Vol. 17, 100248
Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials
- 23 January 2026
- Published by Elsevier in Obesity Pillars
- Vol. 17, 100248
Top Cited PapersOpen AccessNutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials
- Open Access
- 24 December 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (2) , 817-833
Psychometric Validation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity or Overweight
Introduction Obesity management medications influence eating behavior and promote substantial weight reduction in individuals with obesity or overweight. Existing patient-reported outcome measures do not adequately measure appetite and eating behavior concepts relevant to individuals with these conditions. This study presents psychometric properties of the Eating Behavior and Appetite Questionnaire (EBAQ), a new patient-reported outcome measure to assess appetite and eating behaviors in adults with obesity or overweight. Methods Participants (n = 120) completed two web-based surveys (baseline, week 2). Survey 1 included the 21-item EBAQ, Control of Eating Questionnaire, Food Cravings Questionnaire-Trait-reduced, Impact of Weight on Quality of Life-Lite Clinical Trials Version, and Patient Global Impression of Severity (PGIS) items for appetite, eating control, cravings, and overall eating behavior. Survey 2 included the EBAQ and PGIS items. Factor structure, reliability, and validity of the EBAQ were assessed. Results Exploratory factor analysis of the EBAQ supported a 2-factor structure. Items loaded moderately to strongly (≥ 0.48) on factors corresponding to appetite control or eating behavior (inter-factor correlation 0.57). Four items with factor loadings ≤ 0.43 were dropped. Internal consistency for the 17-item EBAQ was good/excellent for the domain scores (0.84–0.91) and excellent for the total score (0.92). Test–retest reliability was good (intraclass correlation coefficients ≥ 0.84). Convergent validity was demonstrated via large correlations with the Control of Eating Questionnaire craving subscales, Food Cravings Questionnaire-Trait-reduced total score, and PGIS items, and smaller correlations with less similar PRO measures. EBAQ domain and total scores demonstrated known-groups validity, with higher EBAQ scores in participants who reported a well-controlled appetite, feeling in control of their eating, fewer food cravings, and better eating habits (i.e., higher PGIS scores). Conclusion Results support the 2-factor structure, reliability, and validity of the final 17-item EBAQ. The EBAQ can be used in observational studies, clinical trials, and clinical practice to comprehensively assess appetite and eating behaviors in individuals with obesity or overweight.
- 24 December 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (2) , 817-833
Open AccessPsychometric Validation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity or Overweight
Introduction Obesity management medications influence eating behavior and promote substantial weight reduction in individuals with obesity or overweight. Existing patient-reported outcome measures do not adequately measure appetite and eating behavior concepts relevant to individuals with these conditions. This study presents psychometric properties of the Eating Behavior and Appetite Questionnaire (EBAQ), a new patient-reported outcome measure to assess appetite and eating behaviors in adults with obesity or overweight. Methods Participants (n = 120) completed two web-based surveys (baseline, week 2). Survey 1 included the 21-item EBAQ, Control of Eating Questionnaire, Food Cravings Questionnaire-Trait-reduced, Impact of Weight on Quality of Life-Lite Clinical Trials Version, and Patient Global Impression of Severity (PGIS) items for appetite, eating control, cravings, and overall eating behavior. Survey 2 included the EBAQ and PGIS items. Factor structure, reliability, and validity of the EBAQ were assessed. Results Exploratory factor analysis of the EBAQ supported a 2-factor structure. Items loaded moderately to strongly (≥ 0.48) on factors corresponding to appetite control or eating behavior (inter-factor correlation 0.57). Four items with factor loadings ≤ 0.43 were dropped. Internal consistency for the 17-item EBAQ was good/excellent for the domain scores (0.84–0.91) and excellent for the total score (0.92). Test–retest reliability was good (intraclass correlation coefficients ≥ 0.84). Convergent validity was demonstrated via large correlations with the Control of Eating Questionnaire craving subscales, Food Cravings Questionnaire-Trait-reduced total score, and PGIS items, and smaller correlations with less similar PRO measures. EBAQ domain and total scores demonstrated known-groups validity, with higher EBAQ scores in participants who reported a well-controlled appetite, feeling in control of their eating, fewer food cravings, and better eating habits (i.e., higher PGIS scores). Conclusion Results support the 2-factor structure, reliability, and validity of the final 17-item EBAQ. The EBAQ can be used in observational studies, clinical trials, and clinical practice to comprehensively assess appetite and eating behaviors in individuals with obesity or overweight.
- Open Access
- 11 November 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (1) , 529-538
Medical events and costs associated with metabolic bariatric surgery among adults with type 2 diabetes: A retrospective, matched cohort study
Aims: This study examined rates of metabolic/bariatric surgery (MBS) among adults with type 2 diabetes and obesity (T2D + O). The study also compared glucose‐lowering medication (GLM) use, costs, comorbidities and medical events for individuals with T2D + O who underwent MBS (cases) to those who did not have MBS (controls). Materials and Methods: Optum Market Clarity US data were used. Annual rates of MBS were examined for adults with T2D + O. MBS cases were matched 1:1 without replacement to controls based upon patient demographics and baseline body mass index (BMI) and followed for a 3‐year post‐period. Differences in outcomes were examined between cases and controls. Results: From 2013 through 2022, 0.5% of adults with T2D + O (0.3%, 0.5% and 0.9% for class 1–3 obesity, respectively) underwent MBS. The matched cohort consisted of 5485 cases and 5485 controls. The mean age was 52.9 years (SD = 10.2) and 69.2% were female. Cases, compared with controls, used significantly fewer GLMs, had significantly lower all‐cause drug costs, and generally had lower rates of incident comorbidities in the 3‐year post‐period. MBS was associated with significantly higher all‐cause acute care, outpatient and total costs. MBS was also generally associated with higher rates of post‐period medical events, such as vitamin D deficiency (56.8%) and endoscopy (41.2%). Conclusions: MBS was performed relatively infrequently in adults with T2D + O. Cases, compared with controls, used fewer GLM, had significantly lower post‐period all‐cause drug costs, and lower rates of incident comorbidities, but had significantly higher post‐period all‐cause total medical costs and higher rates of medical events.
- 11 November 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (1) , 529-538
Open AccessMedical events and costs associated with metabolic bariatric surgery among adults with type 2 diabetes: A retrospective, matched cohort study
Aims: This study examined rates of metabolic/bariatric surgery (MBS) among adults with type 2 diabetes and obesity (T2D + O). The study also compared glucose‐lowering medication (GLM) use, costs, comorbidities and medical events for individuals with T2D + O who underwent MBS (cases) to those who did not have MBS (controls). Materials and Methods: Optum Market Clarity US data were used. Annual rates of MBS were examined for adults with T2D + O. MBS cases were matched 1:1 without replacement to controls based upon patient demographics and baseline body mass index (BMI) and followed for a 3‐year post‐period. Differences in outcomes were examined between cases and controls. Results: From 2013 through 2022, 0.5% of adults with T2D + O (0.3%, 0.5% and 0.9% for class 1–3 obesity, respectively) underwent MBS. The matched cohort consisted of 5485 cases and 5485 controls. The mean age was 52.9 years (SD = 10.2) and 69.2% were female. Cases, compared with controls, used significantly fewer GLMs, had significantly lower all‐cause drug costs, and generally had lower rates of incident comorbidities in the 3‐year post‐period. MBS was associated with significantly higher all‐cause acute care, outpatient and total costs. MBS was also generally associated with higher rates of post‐period medical events, such as vitamin D deficiency (56.8%) and endoscopy (41.2%). Conclusions: MBS was performed relatively infrequently in adults with T2D + O. Cases, compared with controls, used fewer GLM, had significantly lower post‐period all‐cause drug costs, and lower rates of incident comorbidities, but had significantly higher post‐period all‐cause total medical costs and higher rates of medical events.
- Open Access
- 31 October 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 1811-1825
Health state utilities associated with obstructive sleep apnea: preferences of patients with OSA and obesity in the UK and the US
Obstructive sleep apnea (OSA) is characterized by repeated episodes of airway obstruction during sleep, resulting in intermittent hypoxia, disrupted sleep, and reduced quality of life. Obesity management medications may provide new options for patients with OSA and obesity. Health state utilities will be needed as inputs in economic modeling conducted to inform decision-making about these medications for treatment of OSA. The purpose of this study was to estimate utilities associated with OSA severity based on preferences of individuals with OSA and obesity. Participants with OSA and obesity (BMI ≥ 30) in the UK and US valued health state vignettes in time trade-off interviews. Vignettes described four levels of OSA severity defined by apnea-hypopnea index: remission (<5), mild (5-14.9), moderate (15-29.9), and severe (≥30). Participants were instructed to imagine having the option to use non-pharmacologic treatment for OSA when valuing the health states. Utilities were first estimated for OSA with these treatment options. Then, for health states where participants imagined using positive airway pressure or another device, they were asked to value the vignettes a second time without this treatment to estimate utilities associated with symptoms of OSA at each severity level. A total of 208 participants (UK = 105; US = 103) completed interviews (50.0% male; mean age = 53.6y). Mean (SD) utilities ranged from 0.93 (0.08) for mild OSA to 0.85 (0.15) for severe OSA when considering health states with the option to use non-pharmacologic treatment. When participants imagined living with the symptoms of OSA without the non-pharmacologic treatment option, mean utilities ranged from 0.89 (0.13) for mild OSA to 0.68 (0.27) for severe OSA. Results provide insight into preferences associated with OSA among people with OSA and obesity. The health state utilities estimated in this study may be useful in cost-effectiveness models evaluating treatments for OSA in individuals with obesity.
- 31 October 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 1811-1825
Open AccessHealth state utilities associated with obstructive sleep apnea: preferences of patients with OSA and obesity in the UK and the US
Obstructive sleep apnea (OSA) is characterized by repeated episodes of airway obstruction during sleep, resulting in intermittent hypoxia, disrupted sleep, and reduced quality of life. Obesity management medications may provide new options for patients with OSA and obesity. Health state utilities will be needed as inputs in economic modeling conducted to inform decision-making about these medications for treatment of OSA. The purpose of this study was to estimate utilities associated with OSA severity based on preferences of individuals with OSA and obesity. Participants with OSA and obesity (BMI ≥ 30) in the UK and US valued health state vignettes in time trade-off interviews. Vignettes described four levels of OSA severity defined by apnea-hypopnea index: remission (<5), mild (5-14.9), moderate (15-29.9), and severe (≥30). Participants were instructed to imagine having the option to use non-pharmacologic treatment for OSA when valuing the health states. Utilities were first estimated for OSA with these treatment options. Then, for health states where participants imagined using positive airway pressure or another device, they were asked to value the vignettes a second time without this treatment to estimate utilities associated with symptoms of OSA at each severity level. A total of 208 participants (UK = 105; US = 103) completed interviews (50.0% male; mean age = 53.6y). Mean (SD) utilities ranged from 0.93 (0.08) for mild OSA to 0.85 (0.15) for severe OSA when considering health states with the option to use non-pharmacologic treatment. When participants imagined living with the symptoms of OSA without the non-pharmacologic treatment option, mean utilities ranged from 0.89 (0.13) for mild OSA to 0.68 (0.27) for severe OSA. Results provide insight into preferences associated with OSA among people with OSA and obesity. The health state utilities estimated in this study may be useful in cost-effectiveness models evaluating treatments for OSA in individuals with obesity.
- Open Access
- 25 October 2025
- Published by Elsevier in Obesity Pillars
- Vol. 16, 100220
Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial
- 25 October 2025
- Published by Elsevier in Obesity Pillars
- Vol. 16, 100220
Open AccessPerceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial
- Open Access
- 1 October 2025
- Published by Elsevier in Obesity Pillars
- Vol. 16, 100214
Exploring the role of digital health technologies in assessing functional mobility and physical activity: Insights from qualitative interviews in adults with obesity or overweight
- 1 October 2025
- Published by Elsevier in Obesity Pillars
- Vol. 16, 100214
Open AccessExploring the role of digital health technologies in assessing functional mobility and physical activity: Insights from qualitative interviews in adults with obesity or overweight
- Open Access
Modeling potential cost‐effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity
Objective: Our objective was to model the potential cost‐effectiveness of tirzepatide as an alternative to lifestyle modification (LSM) for the management of obesity and overweight.Methods: An individual‐level discrete event simulation was implemented in Microsoft Excel linking short‐term outcomes from the SURMOUNT‐1 trial to key obesity‐related complications to estimate costs and health benefits of tirzepatide (5‐mg, 10‐mg, or 15‐mg doses) and LSM over a lifetime time horizon. Treatment‐related changes in cardiometabolic factors were modeled using data from SURMOUNT‐1; the relationship between patient status and risk of obesity complications was obtained from published literature. Modeled complications included cardiovascular events, onset of type 2 diabetes, cancer, osteoarthritis, and sleep apnea. The model simulated 1000 adult patients with overweight or obesity over their lifetimes, applying a 3% annual discount rate to cost and health outcomes. Only direct medical costs were considered.Results: Tirzepatide 5, 10, and 15 mg provided 0.54, 0.55, and 0.61 additional quality‐adjusted life years (QALYs) and additional costs of $79,288, $70,453, and $75,839 versus LSM, yielding incremental cost‐effectiveness ratios of $146,331, $127,644, and $125,053 per QALY gained, respectively.Conclusions: The model predicted that all doses of tirzepatide represent cost‐effective alternatives to LSM for management of overweight and obesity at a willingness‐to‐pay threshold of $150,000 per QALY.
Open AccessModeling potential cost‐effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity
Objective: Our objective was to model the potential cost‐effectiveness of tirzepatide as an alternative to lifestyle modification (LSM) for the management of obesity and overweight.Methods: An individual‐level discrete event simulation was implemented in Microsoft Excel linking short‐term outcomes from the SURMOUNT‐1 trial to key obesity‐related complications to estimate costs and health benefits of tirzepatide (5‐mg, 10‐mg, or 15‐mg doses) and LSM over a lifetime time horizon. Treatment‐related changes in cardiometabolic factors were modeled using data from SURMOUNT‐1; the relationship between patient status and risk of obesity complications was obtained from published literature. Modeled complications included cardiovascular events, onset of type 2 diabetes, cancer, osteoarthritis, and sleep apnea. The model simulated 1000 adult patients with overweight or obesity over their lifetimes, applying a 3% annual discount rate to cost and health outcomes. Only direct medical costs were considered.Results: Tirzepatide 5, 10, and 15 mg provided 0.54, 0.55, and 0.61 additional quality‐adjusted life years (QALYs) and additional costs of $79,288, $70,453, and $75,839 versus LSM, yielding incremental cost‐effectiveness ratios of $146,331, $127,644, and $125,053 per QALY gained, respectively.Conclusions: The model predicted that all doses of tirzepatide represent cost‐effective alternatives to LSM for management of overweight and obesity at a willingness‐to‐pay threshold of $150,000 per QALY.